Labels

Tuesday, December 16, 2008

Linezolid: a pharmacoeconomic review of its use in...[Pharmacoeconomics. 2005] - PubMed Result

Linezolid: a pharmacoeconomic review of its use in...[Pharmacoeconomics. 2005] - PubMed Result

In conclusion, for patients with serious Gram-positive infections, including those caused by suspected or proven multidrug-resistant pathogens such as MRSA, linezolid is an effective and generally well tolerated therapeutic option. Linezolid is currently the only antibacterial agent with good activity against MRSA that can be administered orally (as well as intravenously). It may be particularly useful as an alternative to vancomycin in patients who have impaired renal function, poor or no intravenous access, require outpatient therapy, or who have been unable to tolerate glycopeptides. Healthcare resource use studies and pharmacoeconomic analyses generally support the use of linezolid in some subgroups of patients, although results should be interpreted with due consideration of the study limitations.

Source pubmed